Trial Profile

A randomised trial of the long term clinical effects of raising HDL cholesterol with extended release niacin/laropiprant

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niacin/laropiprant (Primary) ; Ezetimibe/simvastatin; Simvastatin
Indications Cardiovascular disorders; Dyslipidaemias; Myocardial infarction; Stroke
Focus Therapeutic Use
Acronyms HPS2-THRIVE

22 Aug 2019 Results exploring the safety profile of niacin-laropiprant and examining whether any patients were at lower (or higher) risk of its adverse effects published in the Clinical Therapeutics
25 Mar 2013 Adverse events of this trial are reported to be consistent with those in the AIM-HIGH trial (niacin extended-release monotherapy), according to the University of Oxford media release.
11 Mar 2013 Results presented at the 62nd Annual Scientific Session of the American College of Cardiology. Additional information taken from slides presented at the conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com